Researcher comment: The SPIRIT-H2H trial (with Philip Mease)
Lead investigator Philip Mease discusses the findings from the SPIRIT-H2H trial, a phase III head-to-head trial of ixekizumab versus adalimumab in patients with psoriatic arthritis.
Find more on Medicine Matters rheumatology
This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on June 15, 2019.
Create your
podcast in
minutes
It is Free